
MetLife (MET) Stock Forecast & Price Target
MetLife (MET) Analyst Ratings
Bulls say
MetLife is a well-established, diversified insurance company with a strong financial footing and a focus on capital-light, high return business segments. Their expansion in the Latin American market, where they are considered the top life insurer, presents significant growth potential in a region with strong demand for protection and group benefits products. MetLife also benefits from their diverse product suite and high persistency ratio in their Group Benefits segment, making them a one-stop-shop and providing consistent revenue. However, their global presence does expose them to potential geopolitical and international risks. Overall, we believe the company's strategic execution in recent years qualifies them as a premium player in the insurance space and justifies a higher valuation, leading us to upgrade our outlook to Overweight with an expected increase in earnings and EPS for 2026 and 2027. At the same time, we remain cautious due to potential market volatility and the uncertainty of variable investment income's impact on their earnings growth targets.
Bears say
MetLife is a well-established, consistent grower in the life insurance industry, however, their valuation and future prospects do not warrant trading at the same multiples as their higher valued peers like Aflac, Globe Life, Unum, and Principal. Additionally, they face competitive pressures from other global life insurance companies and are at risk from changes in interest rates and credit spreads, which could affect their investment portfolio and profitability. Lastly, while their guidance for variable investment income looks promising, it is one of the few sources of earnings volatility and may not be enough to outweigh the potential risks and challenges facing the company.
This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.
MetLife (MET) Analyst Forecast & Price Prediction
Start investing in MetLife (MET)
Order type
Buy in
Order amount
Est. shares
0 shares